Displaying drugs 13426 - 13450 of 15194 in total
ABX1100
ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.
Investigational
Matched Description: … It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease …
Gluco-Phenylimidazole
Experimental
Cyanocinnoline
Experimental
2-Aminoquinazolin-4(3h)-One
Experimental
(2,6-Dimethylphenoxy)acetic acid
Experimental
Cadralazine
Experimental
2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione
Experimental
PQ-10
Experimental
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
4-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid
Experimental
3,4-Dihydro-2h-Pyrrolium-5-Carboxylate
Experimental
Sri-9662
Experimental
7-cyano-7-deazaguanine
Experimental
N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline
Experimental
4-Phenylfentanyl
4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.
Illicit
Matched Description: … analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and …
Displaying drugs 13426 - 13450 of 15194 in total